Revolution Medicines insider files Form 144 to sell 4,712 shares

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) filing a Form 144 notifies the SEC of a proposed sale of 4,712 shares of common stock, with an aggregate market value of $219,343.60, expected to be sold around 09/15/2025 on NASDAQ. The shares were received as restricted stock unit grants issued on 03/01 of 2022, 2023, 2024 and 2025 totaling 4,712 shares acquired for services rendered. The filer also reported a recent sale on 06/16/2025 of 3,510 shares for gross proceeds of $139,803.30. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 trading plan disclosure if applicable.

Insights

Securities Analyst

TL;DR: Routine insider sale notification: modest share amounts disclosed, likely non-material to company valuation.

The Form 144 reports a proposed sale of 4,712 common shares valued at $219,343.60 and documents prior sales of 3,510 shares for $139,803.30. All shares originate from RSU grants issued on 03/01 of 2022–2025 for services rendered. The filing follows Rule 144 requirements and includes the seller's attestation regarding material non-public information; it notes the potential use of a Rule 10b5-1 plan without specifying plan dates. Given the small absolute size of the transactions relative to typical public-company floats, this disclosure reads as routine insider liquidity rather than a signal of material corporate development.

Corporate Governance Expert

TL;DR: Compliance-focused filing documenting insider RSU-derived sales; procedural disclosure with limited investor impact.

The document itemizes the acquisition dates and nature of the securities (restricted stock unit grants) and records a recent completed sale plus a proposed sale to occur on NASDAQ. It includes the mandatory seller representation about material adverse information and callout for Rule 10b5-1 plan adoption, but does not provide plan adoption dates or additional selling restrictions. From a governance perspective, the filing satisfies disclosure obligations but lacks ancillary detail (e.g., plan dates) that would clarify whether sales are pre-planned or opportunistic.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	4712	219343.60	186933190	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2022	Restricted stock unit grant	Issuer			1232	03/01/2022	Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer			1270	03/01/2023	Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			1302	03/01/2024	Services rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			908	03/01/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Margaret A. Horn c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2025	3510	139803.30

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Revolution Medicines' Form 144 (RVMD) report?

The Form 144 reports a proposed sale of 4,712 common shares (aggregate market value $219,343.60) expected ~09/15/2025, and a prior sale of 3,510 shares on 06/16/2025 for $139,803.30.

Where will the proposed sale of RVMD shares occur?

The filing states the proposed sale is to occur on NASDAQ around 09/15/2025.

How were the shares being sold acquired according to the filing?

All shares to be sold were acquired as restricted stock unit grants from the issuer on 03/01 of 2022, 2023, 2024 and 2025, credited for services rendered.

Did the filer recently sell any RVMD shares?

Yes. The filing discloses a sale on 06/16/2025 of 3,510 shares for gross proceeds of $139,803.30.

Does the Form 144 state whether a Rule 10b5-1 plan is being used?

The notice references Rule 10b5-1 plan adoption or instruction if relied upon but does not provide a specific plan adoption date in the filing.